BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 2, 2026
Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

BioMarin Files Aryplase BLA;EU Filing To Follow This Year

Nov. 30, 2004
By Aaron Lorenzo
BioMarin Pharmaceutical Inc. moved Aryplase (galsulfase) into the FDA's hands, filing for approval of the enzyme-replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), an inherited and life-threatening disease for which no drug therapies are available. (BioWorld Today)
Read More

Cubist Raises More Than $104M In Public Offering

Nov. 24, 2004
By Aaron Lorenzo
Cubist Pharmaceuticals Inc. raised more than $100 million through a larger public offering of its common shares than originally expected. (BioWorld Today)
Read More

Cubist Raises More Than $104M In Public Offering

Nov. 24, 2004
By Aaron Lorenzo
Cubist Pharmaceuticals Inc. raised more than $100 million through a larger public offering of its common shares than originally expected. (BioWorld Today)
Read More

New AGI-1067 Data Good, But Less So Than Previous

Nov. 23, 2004
By Aaron Lorenzo

New AGI-1067 Data Good, But Less So Than Previous

Nov. 23, 2004
By Aaron Lorenzo

OSI, Genentech Receive FDA Approval Of Tarceva For NSCLC

Nov. 22, 2004
By Aaron Lorenzo
The FDA approved a new lung cancer drug, Tarceva (erlotinib), but a surprise in the agency's authorization might have driven down share values in the companies that developed it - OSI Pharmaceuticals Inc. and Genentech Inc. (BioWorld Today)
Read More

OSI, Genentech Receive FDA Approval Of Tarceva For NSCLC

Nov. 22, 2004
By Aaron Lorenzo
The FDA approved a new lung cancer drug, Tarceva (erlotinib), but a surprise in the agency's authorization might have driven down share values in the companies that developed it - OSI Pharmaceuticals Inc. and Genentech Inc. (BioWorld Today)
Read More

ISTA Acquiring Dry Eye Drug Rights From Old Friend Senju

Nov. 19, 2004
By Aaron Lorenzo

ISTA Acquiring Dry Eye Drug Rights From Old Friend Senju

Nov. 19, 2004
By Aaron Lorenzo

Committee Probes Flu Vaccine Shortage, Seeks Plan For 2005

Nov. 18, 2004
By Aaron Lorenzo
View All Articles by Aaron Lorenzo

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 2, 2026.
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Sickle cell illustration

    AND-017 increases RBC and hemoglobin in sickle cell disease

    BioWorld Science
    Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing